An example of secondary resistance to gefitinib (an epidermal growth factor receptor [EGFR] inhibitor) that is frequently observed in lung adenocarcinoma patients, but only infrequently found in cancer cell lines, is the EGFRT790M mutation.15 This evidence concerns the gene EGFR and lung adenocarcinoma.